<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="144548">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01802385</url>
  </required_header>
  <id_info>
    <org_study_id>S4 0296-01</org_study_id>
    <secondary_id>R01NS086312-01</secondary_id>
    <nct_id>NCT01802385</nct_id>
  </id_info>
  <brief_title>Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis</brief_title>
  <acronym>ASTRO-CM</acronym>
  <official_title>Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Infectious Disease Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mbarara University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota - Clinical and Translational Science Institute</source>
  <oversight_info>
    <authority>Uganda: National Council for Science and Technology</authority>
    <authority>Uganda: National Drug Authority</authority>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Data and Safety Monitoring Board</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase III trial to determine whether adjunctive sertraline will lead to improved
      survival 18-week survival.

      There is an initial phase I/II unmasked dose finding pharmacokinetic study of CSF
      concentrations in at least 20 persons.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase III randomized trial to evaluate whether sertraline when added to standard
      amphotericin-based therapy for cryptococcal meningitis, will lead to improved survival .
      Cryptococcal meningitis diagnosis will be made via CSF cryptococcal antigen (CRAG) at time
      of lumbar puncture (LP) with confirmation by CSF culture.  After informed consent, subjects
      that meet eligibility requirements will be able to enter study.  A non-randomized phase I
      dose-escalation study will first be conducted to help optimize dosing for a larger
      randomized phase II study.

      Phase I/II Design: In addition to standard induction therapy for cryptococcal meningitis,
      subjects will receive increasing doses of sertraline in a dose-escalation study design.  The
      first subjects enrolled into the study will receive 100 mg/day of sertraline.  This dose
      will be sequentially increased by 100 mg/day in groups of n=5 up to a maximum of 400mg
      daily.  Total anticipated enrollment: 20 subjects.

      Phase III Design: Subjects will be randomized to standard induction therapy with masked
      placebo or sertraline at 200mg or 400mg/day.  We will use a permutated block randomization
      in a 1:1:1 allocation (n=160 per arm). Total anticipated enrollment: 480 subjects.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>18 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>18-week survival.  There will be two comparisons: between the sertraline 400mg group and placebo, and between the sertraline 200mg group and placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>18 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety and tolerability of adjunctive sertraline (grade 4-5) adverse reactions)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intolerance</measure>
    <time_frame>18 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Time to dose-reduction for intolerance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiologic</measure>
    <time_frame>14 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>2 week CSF culture sterility</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive Performance</measure>
    <time_frame>14 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Quantitative neurocognitive performance score (QNPZ-8) and Center for Epidemiologic Studies in Depression (CES-D) scale at 4 and 14 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early Fungicidal Activity</measure>
    <time_frame>14 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine whether adjunctive sertraline will lead to a faster rate of fungal clearance from cerebrospinal fluid (CSF), as measured by early fungicidal activity (EFA) of clearance of the Cryptococcus colony forming units (cfu) per mL of CSF per day, compared to standard therapy alone.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IRIS and Relapse Incidence</measure>
    <time_frame>18 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Cumulative incidence of CNS cryptococcal-related paradoxical immune reconstitution inflammatory syndrome (IRIS) or culture-positive relapse</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cost analysis</measure>
    <time_frame>18 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cost-benefit of adjunctive sertraline therapy</description>
  </other_outcome>
  <other_outcome>
    <measure>Switching to Open Label Sertraline</measure>
    <time_frame>14 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Incidence of switching from blinded to open-labeled study drug due to severe depression occurring between 4 to 14 weeks.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Cryptococcal Meningitis</condition>
  <condition>Fungal Meningitis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Standard cryptococcal meningitis therapy with amphotericin (0.7-1.0 mg/kg/day) + fluconazole (800-1200mg/day).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sertraline 200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard cryptococcal meningitis therapy with amphotericin (0.7-1.0 mg/kg/day) + fluconazole (800-1200mg/day) plus adjunctive sertraline therapy at 200mg/day for 14 weeks, then tapered over 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sertraline 400mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard cryptococcal meningitis therapy with amphotericin (0.7-1.0 mg/kg/day) + fluconazole (800-1200mg/day plus adjunctive sertraline therapy at 400mg/day for 2 weeks, then 200mg for 12 weeks, and then tapered over 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertraline</intervention_name>
    <arm_group_label>Sertraline 200mg</arm_group_label>
    <arm_group_label>Sertraline 400mg</arm_group_label>
    <other_name>Zoloft</other_name>
    <other_name>Lustral</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cryptococcal meningitis diagnosed by CSF cryptococcal antigen (CRAG)

          -  HIV-1 infection

          -  Ability and willingness of the participant or legal guardian/representative to
             provide informed consent

          -  Willing to receive protocol-specified lumbar punctures

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  Receipt of &gt;=3 doses of amphotericin therapy

          -  Cannot or unlikely to attend regular clinic visits

          -  History of known liver cirrhosis

          -  Presence of jaundice

          -  Pregnancy

          -  Current breastfeeding
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David B Meya, MBCHB MMed</last_name>
    <role>Principal Investigator</role>
    <affiliation>Infectious Disease Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joshua Rhein, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David R Boulware, MD MPH</last_name>
    <role>Study Chair</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David B Meya, MBChB MMed</last_name>
    <email>david.meya@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David R Boulware, MD MPH</last_name>
    <email>boulw001@umn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Infectious Disease Institute</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darlisha Williams, MPH</last_name>
      <email>coat.trial@gmail.com</email>
    </contact>
    <investigator>
      <last_name>David B Meya, MBChB MMed</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mbarara University of Science and Technology</name>
      <address>
        <city>Mbarara</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Conrad Muzoora, MMed</last_name>
      <email>conradmuzoora@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Kabanda Taseera, MMed MSc</last_name>
      <email>kabtash@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Conrad Muzoora, MMed</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kabanda Taseera, MMed MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <link>
    <url>http://www.idi-makerere.com/</url>
    <description>Infectious Disease Institute</description>
  </link>
  <link>
    <url>http://www.accordiafoundation.org</url>
    <description>Accordia Global Health Foundation</description>
  </link>
  <reference>
    <citation>Zhai B, Wu C, Wang L, Sachs MS, Lin X. The antidepressant sertraline provides a promising therapeutic option for neurotropic cryptococcal infections. Antimicrob Agents Chemother. 2012 Jul;56(7):3758-66. doi: 10.1128/AAC.00212-12. Epub 2012 Apr 16.</citation>
    <PMID>22508310</PMID>
  </reference>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 19, 2014</lastchanged_date>
  <firstreceived_date>February 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cryptococcal meningitis</keyword>
  <keyword>cryptococcus</keyword>
  <keyword>meningitis</keyword>
  <keyword>yeast</keyword>
  <keyword>fungus</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Meningitis, Cryptococcal</mesh_term>
    <mesh_term>Meningitis, Fungal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sertraline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
